Cryosite Ltd Asset Resilience Ratio

Latest as of December 2025: 5.65%

Cryosite Ltd asset resilience ratio. Cryosite Ltd (CTE) has an Asset Resilience Ratio of 5.65% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cryosite Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$1.50 Million
≈ $1.06 Million USD Cash + Short-term Investments

Total Assets

AU$26.55 Million
≈ $18.78 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Cryosite Ltd (2016–2025)

Asset resilience ratio of Cryosite Ltd from 2016 to 2025. This chart shows how Cryosite Ltd's Asset Resilience Ratio has changed over time. Read Cryosite Ltd (CTE) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Cryosite Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cryosite Ltd assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$1.50 Million 5.65%
Total Liquid Assets AU$1.50 Million 5.65%

Asset Resilience Insights

  • Limited Liquidity: Cryosite Ltd maintains only 5.65% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Cryosite Ltd Industry Peers by Asset Resilience Ratio

Compare Cryosite Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
Fleury S.A.
SA:FLRY3
Diagnostics & Research 13.87%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Krsnaa Diagnostics Limited
NSE:KRSNAA
Diagnostics & Research 9.90%
Microba Life Sciences Ltd
AU:MAP
Diagnostics & Research 11.53%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%

Cryosite Ltd Asset Resilience Ratio by Year (2016–2025)

Cryosite Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Cryosite Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 20.55% AU$4.00 Million
≈ $2.83 Million
AU$19.46 Million
≈ $13.77 Million
+0.26pp
2024-06-30 20.29% AU$4.00 Million
≈ $2.83 Million
AU$19.71 Million
≈ $13.95 Million
-9.43pp
2023-06-30 29.72% AU$6.73 Million
≈ $4.76 Million
AU$22.65 Million
≈ $16.02 Million
+4.88pp
2022-06-30 24.84% AU$5.34 Million
≈ $3.78 Million
AU$21.50 Million
≈ $15.21 Million
+7.19pp
2021-06-30 17.65% AU$3.88 Million
≈ $2.75 Million
AU$21.99 Million
≈ $15.56 Million
+0.36pp
2020-06-30 17.28% AU$4.06 Million
≈ $2.87 Million
AU$23.50 Million
≈ $16.63 Million
-1.03pp
2019-06-30 18.31% AU$4.24 Million
≈ $3.00 Million
AU$23.17 Million
≈ $16.40 Million
-42.23pp
2018-06-30 60.54% AU$4.69 Million
≈ $3.32 Million
AU$7.74 Million
≈ $5.48 Million
+8.75pp
2017-06-30 51.79% AU$5.09 Million
≈ $3.60 Million
AU$9.83 Million
≈ $6.95 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$9.66 Million
≈ $6.83 Million
--
pp = percentage points

About Cryosite Ltd

AU:CTE Australia Diagnostics & Research
Market Cap
$42.13 Million
AU$59.55 Million AUD
Market Cap Rank
#22300 Global
#785 in Australia
Share Price
AU$1.22
Change (1 day)
+0.00%
52-Week Range
AU$1.00 - AU$1.30
All Time High
AU$1.30
About

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial … Read more